Jury Hears Zantac Cancer Evidence in Illinois Trial Against Boehringer Ingelheim
Manufacturer ignored clear signs of Zantac risks, resulting in two men developing prostate cancer, lawsuit alleges.
Manufacturer ignored clear signs of Zantac risks, resulting in two men developing prostate cancer, lawsuit alleges.
Valsartan settlement fund will be used to disburse payouts that may be made by different generic drug makers, after versions of the hypertension drug were distributed with cancer-causing contaminants.
Selections have been made in case the parties fail to negotiate Valsartan cancer settlements following a first round of bellwether trials expected to begin in late 2025.
Parties will meet with the MDL judge today, to discuss issues scheduling the remaining bellwether trials selected by the Court.
California jury agreed that Boehringer Ingelheim's heartburn drug was dangerous, but was split on whether Zantac caused the bladder cancer diagnosis.
First bellwether trial in the valsartan MDL will involve claims brought by an Alabama man diagnosed with liver cancer, which is the most commonly reported injury caused by the recalled blood pressure drug.
More than 1,270 Valsartan lawsuits are currently awaiting trial, most involving plaintiffs diagnosed with cancer following exposure to the recalled blood pressure drug, who are getting sicker and many are dying.
Zantac settlement must still be approved by individual plaintiffs, but is expected to resolve vast majority of cancer lawsuits filed in state courts.
Nitrosamine contamination has resulted in massive recalls for valsartan, Zantac and other medications, as well as lawsuits by users who developed cancer.
Drug maker is challenging a lower court ruling, which allows Zantac lawsuits in Delaware to move forward to trial over the increased risk of cancer caused by the recalled heartburn medication.